Try our Advanced Search for more refined results
In re: Lipitor Antitrust Lit
Case Number:
14-4202
Court:
Nature of Suit:
Companies
- American Tort Reform Association
- Association for Accessible Medicines
- Pfizer Inc.
- Ranbaxy
- Rite Aid Corp.
Sectors & Industries:
-
September 25, 2018
Sham Petition Suits Are Piercing Big Pharma's Antitrust Shield
A long-standing U.S. Supreme Court doctrine shielding companies that petition the U.S. Food and Drug Administration from antitrust liability is proving increasingly unhelpful to brand-name drugmakers accused of delaying generic-drug rivals by bombarding the FDA with cockamamie scientific arguments.
-
November 27, 2017
Pfizer Wants Justices To Review Lipitor Antitrust Ruling
Pfizer Inc. and generic-drug maker Ranbaxy Inc. have asked the U.S. Supreme Court to review a decision by the Third Circuit to revive allegations in multidistrict litigation accusing Pfizer of making an illegal reverse payment to keep Ranbaxy's generic version of cholesterol drug Lipitor off the market, saying antitrust scrutiny isn't appropriate for "commonplace" and "traditional" settlements such as the one at issue.
-
August 21, 2017
3rd Circ. Revives Lipitor, Effexor Antitrust Claims
The Third Circuit on Monday handed a sweeping victory to buyers of cholesterol drug Lipitor and antidepressant drug Effexor XR, reviving their antitrust claims for alleged patent fraud and anti-competitive reverse payment schemes.
-
April 13, 2017
3rd Circ. Will Decide Lipitor, Effexor Pay-For-Delay Suits
The Third Circuit on Thursday said it has jurisdiction to consider the merits of two appeals of lower court dismissals of alleged pay-for-delay litigation over the drugs Lipitor and Effexor XR, rejecting calls by the pharmaceutical companies involved in the cases to transfer them to the Federal Circuit.
-
September 27, 2016
Lipitor Buyers Ask 3rd Circ. To Keep Pay-For-Delay Fight
Attorneys for national pharmacies and wholesale drug distributors told the Third Circuit on Tuesday that their dismissed suit accusing Pfizer and Ranbaxy of a pay-for-delay scheme over the cholesterol drug Lipitor did not belong in the Federal Circuit, in an argument the appeals court confined to the question of jurisdiction.
-
May 27, 2016
Lipitor Retailers Push 3rd Circ. To Revive Pay-For-Delay Claims
Walgreen, Rite Aid and other retailers urged the Third Circuit Friday to revive claims that Pfizer paid Ranbaxy to postpone releasing a generic of the cholesterol drug Lipitor and said Pfizer's argument that the case should go to the Federal Circuit if the district court's dismissal is overturned is incorrect.
-
March 29, 2016
Pharma Groups Back Pfizer In 3rd Circ. Pay-For-Delay Case
Pharmaceutical groups on Monday asked the Third Circuit not to revive claims that Pfizer Inc. illegally paid Ranbaxy Laboratories Inc. to postpone its generic of cholesterol drug Lipitor, arguing that all agreements were legal under the U.S. Supreme Court's Actavis decision and that the retailers bringing the suit lacked evidence.
-
March 22, 2016
Pfizer Urges 3rd Circ. Not To Revive Lipitor Antitrust Row
Pfizer has urged the Third Circuit to either uphold a New Jersey federal court’s dismissal of claims that it paid Ranbaxy to postpone releasing a generic of the cholesterol drug Lipitor, or to transfer the case to the Federal Circuit because it contains fraud claims involving the U.S. Patent and Trademark Office.
-
January 04, 2016
Profs Weigh In On 3rd Circ. Lipitor Pay-For-Delay Row
A group of 48 professors has joined the American Antitrust Institute in urging the Third Circuit to revive allegations that Pfizer paid Ranbaxy to postpone a generic version of Lipitor, saying a New Jersey judge shirked precedent by tossing the pay-for-delay suit based on impossibly high standards.
-
December 21, 2015
Walgreens Pushes Lipitor Pay-For-Delay Row At 3rd Circ.
Walgreens, Rite Aid and other retailers told the Third Circuit that a lower court hastily dismissed their Lipitor pay-for-delay suit, saying Friday they had presented plenty of evidence that Pfizer paid Ranbaxy to postpone releasing a generic of the cholesterol drug.